Trials / Completed
CompletedNCT01450488
Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- AB Science · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | masitinib | masitinib 3 mg/kg/day |
| DRUG | masitinib | masitinib 6 mg/kg/day |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2007-07-01
- Completion
- 2010-01-01
- First posted
- 2011-10-12
- Last updated
- 2018-12-11
Source: ClinicalTrials.gov record NCT01450488. Inclusion in this directory is not an endorsement.